ArticleScientific reports2025
The correlation between proprotein convertase subtilisin/kexin type 9 and adiponectin in the progression from prediabetes to type 2 diabetes mellitus.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Data on the involvement of proprotein convertase subtilisin/kexin type 9 (PCSK9) and adiponectin in prediabetes progression to type 2 diabetes mellitus (T2DM) remains inconclusive. Therefore, this study investigated the roles of PCSK9 and adiponectin in this process. This study included 1,528 participants with prediabetes and T2DM and conducted correlation analyses to investigate the relationship between PCSK9 and adiponectin levels, pancreatic beta-cell function, and insulin levels. Logistic regression analysis and receiver operating characteristic (ROC) curves were used to determine whether PCSK9 and adiponectin play protective roles in the progression from prediabetes to T2DM and their potential as diagnostic biomarkers for T2DM. In prediabetic patients, the levels of PCSK9 [573.00 (412.35) ng/mL vs. 924.20 (673.38) ng/mL, p < 0.001] and adiponectin [4.50 (2.80) mg/mL vs. 6.22 (4.51) mg/mL, p < 0.001] were significantly higher than those in patients with T2DM. PCSK9 (r = 0.167, p < 0.001) and adiponectin (r = 0.113, p < 0.001) levels were positively correlated with pancreatic cell homeostasis and had protective effects against progression from prediabetes to T2DM (PCSK9: OR = 0.274, 95% CI 0.121-0.621, p = 0.002; adiponectin: OR = 0.135, 95% CI 0.057-0.320, p < 0.001). The combined diagnostic value of PCSK9 and adiponectin for T2DM showed an area under the curve of 0.751 (95% CI 0.727-0.775). Prediabetes and T2DM patients showed significant differences in the PCSK9 and adiponectin levels. PCSK9 and adiponectin have protective effects against the progression of prediabetes to T2DM, and their combined use is a potential biomarker for the transition from prediabetes to T2DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.